Celebrates 30 Years of Innovation Through
Collaboration and the Development of Technologies That Have Helped
Set the Standard of Care for the Industry
MADISON,
Wis., April 25, 2024 /PRNewswire/
-- Accuray Incorporated (NASDAQ: ARAY) announced today that
the company is showcasing advances in hardware and software
designed to improve the cancer treatment experience, at ESTRO 2024.
The latest generation CyberKnife® and
Radixact® platforms provide medical care teams with the
technology necessary for expanding the curative power of radiation
therapy and delivering on the focus of this year's congress,
bridging the care gap. The European Society for Radiotherapy and
Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.
"This year's ESTRO meeting is particularly meaningful as we
recognize – and celebrate – 30 years of collaborating with
healthcare professionals and industry partners to develop
ground-breaking technologies that expand the application of
radiation therapy and access to patients who may benefit from care.
The precision and accuracy of the CyberKnife and Radixact Systems
enable our customers to personalize the way cancer is managed for
each patient throughout their treatment journey while also treating
more patients, better and faster, than ever before," said
Suzanne Winter, Winter, president
and CEO of Accuray.
Accuray is a wellness focused organization, taking into account
the patient's health and well-being throughout their treatment when
prioritizing product enhancements. The solutions featured at ESTRO
represent a few of the most recent innovations introduced over a 30
year history of invention and disruption that has led to new
standards in care for the radiation therapy industry. Visit Accuray
at booth #480 to learn more.
"Accuray takes pride in our legacy of breakthroughs in cancer
and neuro-radiosurgical technology. The CyberKnife System was the
first platform to integrate robotic mobility with real-time imaging
to address tumor motion, allowing unparalleled precision without
the requirement of uncomfortable stereotactic frames," said Seth
Blacksburg, M.D., MBA, Chief Medical Officer at Accuray. "With the
TomoTherapy System—the precursor to the Radixact System—we
furthered our impact by being the first to merge computed
tomography (CT) with intensity-modulated radiation therapy (IMRT)
within one system, enabling clinicians to deliver targeted helical
radiation therapy designed to meticulously match the tumor's
complex shape."
Continued Dr. Blacksburg, "These innovations enable medical care
teams worldwide to confidently and non-invasively treat a wide
assortment of malignant and benign disease while minimizing the
effect on healthy tissues. Our collaboration with world class
physicians and engineers continues to forge improvements in
oncology and neuro-radiosurgery, empowering the development of
novel solutions that advance—and personalize—patient care."
Accuray ESTRO 2024 Highlights: Technologies as Unique as the
People for Whom They're Designed
- Radixact System: Built-in CT scanner enables fast helical
imaging, producing the high-quality images necessary for treatment
planning. Uniformity in image quality and consistency in Hounsfield
units validate their use in this important step in the radiation
therapy treatment workflow.
ClearRT™ enhanced imaging on the Radixact® System
enables clinicians to easily, quickly and cost effectively acquire
exceptional quality images. The applications of ClearRT imaging for
accurate and precise radiation therapy are multi-fold: for fast and
accurate image guided patient setup, in use with the Accuray
proprietary Synchrony® technology for real-time
adaptation of treatment delivery and as the input for monitoring
and adapting a patient's treatment plan as needed during the course
of treatment with PreciseART® radiotherapy.
- CyberComm™: A new physics offering intended to significantly
reduce the CyberKnife® S7™ System's commissioning time
and enable customers to begin treating patients significantly
faster.
- Cenos™* (work in progress): Designed to provide customers with
the ability to perform online adaptation of their treatment plan to
account for changes that may occur between treatment sessions. This
latest innovation from Accuray for the Radixact System is intended
to enable clinical teams to adapt on-demand based on the needs of
the patient, ensuring clinical objectives are met while providing
flexibility to optimize and streamline adaptive workflows.
Symposium: Navigating The Oligometastatic Frontier: A
Comprehensive Didactic and Roundtable Discussion
- Saturday, May 4, 2024, from
1:00 pm – 2:00
pm BST in the Boisdale room
- Features experts from Universities of Turin, Milan
and Ghent, and The Royal Marsden Hospital
- Click here to learn more
AEx Webinar: Harnessing the Power: Radixact®
System and SGRT
- Monday, May 6, 2024 at
7.30am EDT - 12.30pm BST -
1.30pm CEST - 7.30pm HK
- Learn about SGRT with the Radixact System and VitalHold™ from a
Lund University expert
- Click here to learn more and to register
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations related to our
new product offerings and innovations; our ability to enable
improvements in the development of personalized patient treatment;
our ability to set new standards in care for the industry; clinical
results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products; the company's ability to develop
new products or improve existing products to meet customers' needs;
the company's ability to anticipate or keep pace with changes in
the marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
February 7, 2024, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
*Cenos™ is a work in progress. The solution is not available
for sale in the USA. It is not CE
marked and availability is subject to regulatory clearance or
approval in some markets.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-showcases-advances-in-radiation-therapy-solutions-designed-to-improve-the-cancer-treatment-experience-at-estro-2024-302127079.html
SOURCE Accuray Incorporated